HIIT Following Breast Cancer Chemotherapy

Description

Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.

Conditions

Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.

High Intensity Interval Training: Optimizing Exercise Therapy to Mitigate Cardiovascular Disease Risk Following Breast Cancer Chemotherapy

HIIT Following Breast Cancer Chemotherapy

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Gainesville

Integrative Cardiovascular Physiology Laboratory, University of Florida, Gainesville, Florida, United States, 32611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * female patients based on biological sex
  • * 18 to 85 years of age
  • * diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer
  • * completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation
  • * absence of contraindications to exercise or to participate in study
  • * study clinician approval
  • * do not meet inclusion criteria
  • * scheduled to receive surgery or radiation therapy during the intervention period
  • * any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
  • * lymphedema stage ≥2 prior to study enrollment
  • * are pregnant
  • * current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Florida,

Demetra Christou, PhD, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

2026-05-31